BIO vs WAT
BIO: Bio-Rad provides essential tools and services for life science research and clinical diagnostics to help advance scientific discovery and improve patient outcomes. WAT: A global leader in analytical instruments and life science diagnostics that recently transformed through a major acquisition to significantly expand its clinical and multiomics capabilities.
Side-by-side fundamentals
| Metric | BIO | WAT | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $352.47 | $406.86 | |
| Market cap as of 2026-08-10 | $9.8B | $39.9B | |
| P/E as of 2026-08-10 | 42.65 | 240.45 | BIO lower |
| Net margin as of 2026-08-10 | +8.6% | +3.6% | BIO higher |
| Gross margin as of 2026-08-10 | +51.9% | +50.9% | BIO higher |
| Operating margin as of 2026-08-10 | +1.8% | +7.1% | WAT higher |
| ROE as of 2026-08-10 | +3.1% | +1.9% | BIO higher |
| ROA as of 2026-08-10 | +2.2% | +1.1% | BIO higher |
| Debt / equity as of 2026-08-10 | 0.17 | 0.33 | BIO lower |
| Revenue growth (YoY) as of 2026-08-10 | +1.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -2.7% | +2.1% | WAT higher |
| Beta as of 2026-08-10 | 1.07 | 1.16 | |
| 1-year return as of 2026-08-07 close | +32.9% | +46.4% | WAT higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.